Taysha Gene Therapies, Inc. (TSHA) insider trading

By person

8 insiders · 12 transactions

28.0×

Sean Nolan holds 28.0 times base salary in stock. $18.15M of shares against $645.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Sean Nolan last reported holding, valued at $6.24, the price Common Stock was last bought or sold at on the open market here, on 10 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Sukumar Nagendran

President and Head of R&D

—

$5.33M (7) scheduled

−$5.33M

936,410

0.2874%

$5.84M

+4.3%

Sean P. Nolan

Chief Executive Officer

—

$840.20K (2)

−$840.20K

2,908,257

0.8926%

$18.15M

+145.2%

Kamran Alam

Chief Financial Officer

—

$492.52K (3)

−$492.52K

1,442,131

0.4426%

$9.00M

+71.5%

Paul B Manning

10% owner

—

2,841,704

0.8721%

$17.73M

+35.9%

John A Stalfort III

Director

—

1,176,559

0.3611%

$7.34M

+7.1%

Phillip B. Donenberg

Director

—

241,289

0.0741%

$1.51M

+47.7%

Alison S Long

Director

—

127,178

0.0390%

$793.59K

+158.4%

Laura Sepp-Lorenzino

Director

—

127,178

0.0390%

$793.59K

+158.4%

Taysha Gene Therapies, Inc.

What the insiders did Net selling

By person